D uring the past decade, the repair of abdominal aortic aneurysms (AAAs) has transitioned from open surgical repair to endovascular aortic aneurysm repair (EVAR). 1 Because of significant concerns regarding the longterm durability of EVAR, [2] [3] [4] 
the Society of Vascular Surgery (SVS)
advises surveillance with computed tomographic (CT) scanning at 1 and 12 months during the first postoperative year, followed by CT scanning every 12 months thereafter, with the alternative option of ultrasonography if no abnormality was detected during the first year. [2] [3] [4] [5] However, recent observations have begun to challenge these guidelines for lifelong surveillance as too conservative. 6, 7 Singlecenter studies 6, 7 have been unable to show that patients with incomplete surveillance have poorer outcomes compared with those with complete surveillance. Other publications [8] [9] [10] [11] [12] [13] argue that less frequent surveillance is sufficient for most patients and that the first postoperative CT scan should be used to stratify patients by risk and adjust surveillance guidelines accordingly. Although noteworthy, these studies were fundamentally limited in that they could not distinguish whether participants were lost to or unavailable for follow up or whether they received care elsewhere. We sought to use 10 years of Medicare claims data to corroborate that nonadherence to SVS surveillance guidelines does not lead to worse long-term aneurysmrelated outcomes after EVAR.
Methods

Data Set
We used claims from a 20% sample of Medicare fee-forservice beneficiaries from January 1, 2002, through December 31, 2011. Diagnoses and hospital procedures were identified from the Medical Provider and Analysis Review (MedPAR, part A) using the codes from the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), reported for each inpatient admission. Physician procedures were identified from the physician Carrier files (part B) using Current Procedural Terminology (CPT) codes reported on each physician claim. Demographic data, Medicare enrollment information, and mortality were collected from the Medicare denominator and beneficiary summary files. Our investigation received approval by the institutional review board of Stanford School of Medicine, which granted a waiver of consent. Patient data were deidentified.
Patient Cohort
We identified patients who underwent AAA-related EVAR from January 14 Patients with a secondary intervention or complication were categorized as having complete or incomplete surveillance based on the status of their surveillance at the time of the secondary intervention or complication.
Other measures included in the analysis were comorbidity, estimated as described by Elixhauser et al, 15 and the annual AAA repair volume of the hospital at which the initial EVAR was performed, categorized into quintiles. Hospitals in the lowest quintile were defined as low-volume hospitals, and those in the highest quintile were defined as high-volume hospitals. Using the Medicare denominator and beneficiary summary files, patients' age, sex, race, and Medicaid eligibility status were recorded. The US Department of Agriculture census-based Rural Urban Commuting Area codes 16 were used to categorize patients' residence as urban or rural as described previously.
Statistical Analysis
Data analysis was performed from January 1, 2002, through December 31, 2011. We performed unadjusted comparisons of the outcomes of interest between patients with and without complete surveillance in unmatched and matched cohorts. We used a 2-tailed t test to analyze normally distributed continuous variables and a Wilcoxon signed rank test for nonparametric data. We analyzed categorical variables using a χ 2 test.
Kaplan-Meier survival curves were computed to assess the time to event and compared using log-rank analysis. Multivariable logistic regression modeling was performed on the unmatched cohort controlling for all demographic variables, including age, sex, race, Medicaid eligibility, residential status, hospital volume, ruptured AAA, and all preexisting comorbidities (ie, valvular disease, congestive heart failure, peripheral vascular disease, hypertension, diabetes mellitus, pulmonary disease, renal failure, lymphoma, metastatic cancer, and solid tumor). Goodness of fit of logistic models was evaluated using the McFadden pseudo-R 2 value.
All statistical analyses with P values of less than .05 were considered significant. We used 2 commercially available statistical software programs for data extraction and management (SAS, version 9.1.3; SAS Institute Inc) and for data analysis (STATA, version 13.0; StataCorp). Mean (SD) duration of follow-up was 5.2 (2.9) years with a median follow-up duration of 6.1 years and interquartile range of 2.6 to 7.4 years. Of our cohort, we observed complete surveillance in 4169 patients (43.0%) and incomplete surveillance in the remaining 5526 patients (57.0%), including 497 (5.1%) who received no documented follow-up imaging. Among patients with incomplete surveillance, 2349 (42.5%) had gaps in surveillance, 1989 (36.0%) were lost to or unavailable for follow-up, and 1188 (21.5%) had both.
14 After propensity matching, a total of 7888 patients constituted the matched cohort, with 3944 (50.0%) in the complete surveillance group and 3944 (50.0%) in the incomplete surveillance group. Table 1 describes the characteristics of these patients stratified by surveillance status before and after propensity matching. In the unmatched cohort, the AAA-related complications were observed in 393 patients (4.1%), including late rupture in 99 (1.0%), major reinterventions in 15 (0.2%), and minor reinterventions in 314 (3.2%). For patients in the matched cohort, patients with incomplete surveillance experienced lower rates of total complications (1.6% vs 7.3%, P < .001), late rupture (0.7% vs 1.4%, P = .001), and major or minor reinterventions (1.2% vs 6.2%; P < .001) ( Table 2 ). All-cause mortality was observed in 44.2% of the entire matched cohort and was lower among those with incomplete surveillance (28.7% vs 59.7%; P < .001). Aneurysm-related mortality was observed in 0.5% of the entire cohort and was not significantly different between those with incomplete and complete surveillance (0.3% vs 0.6%; P = .07). Consistent results were found in the unmatched cohort; patients with incomplete surveillance experienced lower rates of total complications (89 [ Table 3 shows adjusted comparisons of postoperative complications per year stratified by surveillance status. By postoperative year 10, patients in the incomplete surveillance group experienced lower rates of total complications (2.1% vs 14.0%; P < .001), late rupture (1.1% vs 5.3%; P < .001), major or minor reinterventions (1.4% vs 10.0%; P < .001), aneurysm-related mortality (0.4% vs 1.3%; P < .001), and all-cause mortality (30.9% vs 68.8%; P < .001).
In the unmatched cohort, the first postoperative CT scan was obtained within 30 days in 3085 patients (31.8%) and within 60 days in 5896 patients (60.8%). In a multivariable logistic regression, incidence of any complication (late rupture or any reintervention) was independently associated with receiving a postoperative CT scan within 30 days (odds ratio, 1.25 [95% CI, 1.02-1.55]; P = .03).
Discussion
To our knowledge, this study is the first US population-based investigation of the relationship between adherence to low-up after EVAR was not associated with adverse AAArelated outcomes, including incidence of endoleak, device migration, reintervention, or AAA-related mortality compared with patients who received frequent follow-up. These investigators 7 also observed that patients with frequent follow-up paradoxically experienced a higher incidence of these adverse outcomes. Early or persistent endoleak after EVAR may have led to increased surveillance and increased interventions that did not improve AAA-related mortality. 7 Because the goal of postoperative surveillance is to prevent AAA-related mortality, our findings suggest that not all patients require yearly imaging after EVAR. Although the SVS recommends annual surveillance because of significant concerns regarding the long-term durability of EVAR, [2] [3] [4] we found that only 7.2% of patients with complete surveillance experienced a complication (late rupture or any reintervention), and 6.2% required a reintervention. These findings are similar to those of Dias et al, 8 who found that only 20 of 304 patients (6.6%) undergoing annual CT surveillance after EVAR required reintervention. Only a few patients may benefit from Although we found no difference in the incidence of aneurysm-related mortality between patients with complete and incomplete surveillance, we observed a lower incidence of allcause mortality in patients with incomplete surveillance. Although these data may appear paradoxical, our findings are comparable with those of previous studies reporting that patients with complete surveillance had worse overall survival. 6, 7 Similar to previous authors, 6 we hypothesize that patients with other considerable medical conditions that increase the risk for death may be more likely to have physician visits and undergo surveillance. In addition, patients who develop other serious illness subsequent to EVAR are more likely to receive additional imaging-not necessarily for surveillance purposes-and are subject to increased mortality unrelated to AAA or EVAR. Our study supports the need for better defined post-EVAR surveillance guidelines that protect patients from adverse outcomes while appropriately using medical resources. Previous studies [9] [10] [11] [12] [13] have proposed that long-term surveillance guidelines should be based on risk stratification using clinical indicators, especially because certain preoperative anatomic features, intraoperative findings, and postoperative abnormalities have been associated with adverse outcomes after EVAR. For example, Bastos Gonçalves et al 9 found that a normal result on a postoperative CT scan within 17 days of EVAR significantly reduced the risk for aneurysm-related adverse events during a median follow-up of 4.1 years, thus resulting in a large number of unnecessary imaging events for these lowrisk patients. The authors 9 concluded that the first postoperative CT scan should be used to stratify patients based on risk and that the surveillance guidelines should be adjusted accordingly. Similarly, another study 19 used data from the US Zenith Endovascular multicenter trial and found that freedom from endoleak at 1 month was highly predictive of reduced aneurysm-related mortality, thus leading the authors to conclude that a new EVAR surveillance regimen based on early outcomes is needed. In the present study, we found that most patients receive a postoperative CT scan within 6 months of EVAR; thus, using a risk-stratification protocol based on the first CT might be a viable solution to optimizing surveillance guidelines. In addition to the frequency, the modality of long-term surveillance has also been questioned, especially because CT is associated with higher costs compared with ultrasonography. [20] [21] [22] The study by Dias et al 8 found that only 20 of 304 patients (<10%) undergoing annual CT surveillance had a reintervention, leading the authors to conclude that non-contrast-enhanced CT or ultrasonography might be an appropriate modality of surveillance. Similarly, Bastos Gonçalves et al 9 and Sternbergh et al 19 also concluded that ultrasonography might be an acceptable substitution for CT for long-term surveillance. Several studies comparing CT and ultrasonography [23] [24] [25] [26] have concluded that ultrasonography is a viable and highly sensitive substitution for CT in detecting endoleaks and that it does not affect the incidence of secondary interventions. Routine surveillance using an ultrasonography-first approach likely would have a substantially beneficial effect on the cumulative costs of postoperative surveillance without sacrificing quality of care. Further research is needed to quantify the amount of cost savings. Our study is subject to limitations owing to the nature of administrative data. As with all studies using administrative data, we were unable to collect clinical information, such as the presence or absence of endoleak and other clinical conditions that may have prompted postoperative imaging. Such clinical information would have provided additional information for our analysis. Our intent was to investigate all postoperative imaging to capture all instances of potential post-EVAR surveillance. Furthermore, administrative data may be 
